Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Expert Review of Precision Medicine and Drug Development is Scopus-indexed (Q3, CiteScore 2.3), WoS ESCI. Published by Taylor and Francis Ltd..
Checked against the index lists dated .
ISSN 2380-8993Verify ISSN ↗
Publisher: Taylor and Francis Ltd.
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology | 235 / 328 | 28th | Q3 |
| Drug Discovery | 124 / 161 | 23rd | Q4 |
| Genetics | 279 / 357 | 21st | Q4 |
| Molecular Medicine | 151 / 179 | 15th | Q4 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2016–2025, best quartile Q3, CiteScore 2.3.
Expert Review of Precision Medicine and Drug Development is Q3 in Pharmacology (rank 235 of 328), Q4 in Drug Discovery (rank 124 of 161) and Q4 in Genetics (rank 279 of 357), by CiteScore 2025. It is ranked in 4 subject areas in all.
Expert Review of Precision Medicine and Drug Development is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 2.3, which places it in quartile Q3 at the 28th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.250, quartile Q3, with an H-index of 19.
Expert Review of Precision Medicine and Drug Development is published by Taylor and Francis Ltd. Its ISSN is 2380-8993.
Yes — indexed in the Emerging Sources Citation Index.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Expert Review of Precision Medicine and Drug Development has an h-index of 22 and a 2-year mean of 3.4 citations per paper (OpenAlex). Its Scopus CiteScore is 2.3, quartile Q3. On 2-year citations it ranks #98 of 319 Scopus journals in Pharmacology.
Expert Review of Precision Medicine and Drug Development published 4 papers in 2025; its busiest recent year was 2020 with 53. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 48 research articles (2021–2025), authors are most often from United States (31.9%), Italy (20.8%) and India (6.9%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.